Overview

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine
Pemetrexed